Key person interview
Words of co-creation, words of symbiosis
Collection of key person interviews
We will tell you about people's passion for drug discovery.
Deliver new drugs to Underserved Therapeutic Areas. To that end, SymBio Pharmaceuticals' activities are supported not only by our employees, but also by many other people. We interviewed key people inside and outside the company about episodes of new drug development, past and future business prospects, and expectations for SymBio Pharmaceuticals. The passion of people spread around drug discovery. Please listen to the words that are born from there.
The "Key Person Interview Collection" is included to provide our stakeholders with information related to our company. Although it may contain information on ethical drugs and development products, it is intended to provide information to the press, shareholders, and investors, and is intended for promotion, advertising, medical advice, etc. It is not intended to be
■Dear Experts
-
NEW
We are grateful to SymBio Pharmaceuticals for their efforts in developing new drugs to treat glioblastoma
Neurosurgery and Neuro-oncology Division, National Cancer Center Hospital
Dr. Yoshitaka Narita
-
NEW
BCV in Hematology and Oncology:
A 3-Year Journey from Laboratory to Clinical Trials
Senior Consultant Division of Medical Oncology, National Cancer Centre Singapore
Assistant Professor at Duke-NUS Medical School
Jason Chan, MBBS, MRCP (UK), MMed (Internal Medicine), FAMS (Medical Oncology), PhD (Cancer Biology)
-
The presentation at the ASH meeting in 2023 has reignited
incredible enthusiasm about this drug to treat Adenovirus.
Medical Director, Bone Marrow Transplant and Immune Deficiency
Cancer and Blood Diseases Institute Cincinnati Children's Hospital Medical Center Cincinnati, OH USA
Michael Grimley, MD Professor of Pediatrics -
Resistance to viral infections after hematopoietic stem cell transplantation
I want to support the development of new medicines in Japan.Fujita Health University
Professor, Department of Hematopoietic Cell Transplantation and Cellular Therapy
Professor Masahiro Inamoto
■ SymBio Pharmaceutical members
-
NEW
Tackling Broad Indications with Brincidofovir:
Achievements So Far and Expectations for the FutureTranslational Research Division,
Medical Advisor MD, PhD
Tetsu Kamitani -
The diverse results obtained through joint research
We hope to use this knowledge to advance clinical developmentCSO and Director of Translational Research
Masaaki Hasama